Prognosis
Intellia Gains After Strong Results in Landmark Crispr Study
- Small, early-stage trial fuels hopes for genetic therapies
- Study elicits signs of treating an inherited liver disease
Photographer: Gregor Fischer/dpa/Getty Images
This article is for subscribers only.
In a milestone for gene therapy, drugmakers Intellia Therapeutics Inc. and Regeneron Pharmaceuticals Inc. reported results from the first clinical trial using Nobel Prize-winning Crispr technology to treat disease inside the human body.
The study of six patients showed significant reductions in levels of a harmful liver protein associated with a genetic disease, the companies said Saturday.